| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 59 | 2025 | 671 | 7.250 |
Why?
|
| Depressive Disorder | 12 | 2017 | 449 | 2.160 |
Why?
|
| Cognition Disorders | 9 | 2022 | 555 | 1.520 |
Why?
|
| Anxiety Disorders | 10 | 2017 | 674 | 1.470 |
Why?
|
| Stress Disorders, Post-Traumatic | 6 | 2025 | 622 | 1.250 |
Why?
|
| Depression | 18 | 2020 | 1217 | 1.050 |
Why?
|
| Psychiatric Status Rating Scales | 15 | 2018 | 796 | 1.030 |
Why?
|
| REM Sleep Behavior Disorder | 2 | 2025 | 16 | 1.000 |
Why?
|
| Anxiety | 13 | 2019 | 956 | 0.940 |
Why?
|
| Mental Disorders | 7 | 2016 | 820 | 0.910 |
Why?
|
| Aggression | 1 | 2024 | 225 | 0.770 |
Why?
|
| Neurodegenerative Diseases | 2 | 2022 | 253 | 0.680 |
Why?
|
| Sleep Wake Disorders | 1 | 2021 | 173 | 0.650 |
Why?
|
| Dementia | 4 | 2014 | 448 | 0.640 |
Why?
|
| Cognitive Dysfunction | 1 | 2022 | 225 | 0.610 |
Why?
|
| Dystonia | 2 | 2020 | 171 | 0.530 |
Why?
|
| Psychotic Disorders | 4 | 2019 | 140 | 0.520 |
Why?
|
| Veterans | 6 | 2025 | 1733 | 0.510 |
Why?
|
| Aged | 37 | 2025 | 19094 | 0.480 |
Why?
|
| Comorbidity | 11 | 2020 | 1496 | 0.470 |
Why?
|
| Surveys and Questionnaires | 11 | 2018 | 3666 | 0.460 |
Why?
|
| Middle Aged | 41 | 2025 | 25992 | 0.460 |
Why?
|
| Depressive Disorder, Major | 3 | 2020 | 398 | 0.450 |
Why?
|
| Humans | 77 | 2025 | 123072 | 0.450 |
Why?
|
| Panic Disorder | 2 | 2011 | 45 | 0.430 |
Why?
|
| Torticollis | 3 | 2021 | 71 | 0.430 |
Why?
|
| Delusions | 2 | 2012 | 17 | 0.410 |
Why?
|
| Hallucinations | 2 | 2012 | 26 | 0.410 |
Why?
|
| Health Services | 1 | 2012 | 71 | 0.400 |
Why?
|
| Health Status | 2 | 2012 | 374 | 0.400 |
Why?
|
| Illusions | 1 | 2012 | 8 | 0.400 |
Why?
|
| Drug Utilization | 1 | 2013 | 159 | 0.390 |
Why?
|
| Disclosure | 1 | 2013 | 154 | 0.380 |
Why?
|
| Multiple Sclerosis | 1 | 2015 | 335 | 0.380 |
Why?
|
| Family Health | 3 | 2011 | 259 | 0.380 |
Why?
|
| Nootropic Agents | 2 | 2009 | 25 | 0.380 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 1 | 2010 | 32 | 0.360 |
Why?
|
| Ubiquitin-Protein Ligases | 5 | 2014 | 352 | 0.360 |
Why?
|
| Aged, 80 and over | 17 | 2020 | 6371 | 0.350 |
Why?
|
| Male | 47 | 2025 | 60081 | 0.340 |
Why?
|
| Antiparkinson Agents | 2 | 2009 | 65 | 0.330 |
Why?
|
| Propylamines | 1 | 2009 | 8 | 0.320 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2009 | 27 | 0.320 |
Why?
|
| Prevalence | 11 | 2020 | 2404 | 0.320 |
Why?
|
| Dystonic Disorders | 2 | 2021 | 83 | 0.300 |
Why?
|
| Female | 44 | 2025 | 65528 | 0.290 |
Why?
|
| Severity of Illness Index | 13 | 2018 | 2848 | 0.280 |
Why?
|
| Cholinesterase Inhibitors | 2 | 2006 | 90 | 0.270 |
Why?
|
| Physical Therapy Modalities | 1 | 2006 | 50 | 0.260 |
Why?
|
| Psychometrics | 6 | 2013 | 657 | 0.250 |
Why?
|
| Prodromal Symptoms | 1 | 2025 | 9 | 0.240 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 4 | 2020 | 201 | 0.240 |
Why?
|
| Alcohol Amnestic Disorder | 1 | 2003 | 2 | 0.230 |
Why?
|
| Polysomnography | 1 | 2025 | 140 | 0.220 |
Why?
|
| Patient Health Questionnaire | 2 | 2020 | 15 | 0.220 |
Why?
|
| Indans | 1 | 2004 | 53 | 0.220 |
Why?
|
| HIV Infections | 1 | 2015 | 1855 | 0.210 |
Why?
|
| Violence | 1 | 2024 | 112 | 0.210 |
Why?
|
| Cross-Sectional Studies | 11 | 2020 | 3371 | 0.210 |
Why?
|
| Mental Health Services | 3 | 2015 | 247 | 0.210 |
Why?
|
| Psychotropic Drugs | 3 | 2011 | 124 | 0.210 |
Why?
|
| Adult | 23 | 2025 | 29010 | 0.200 |
Why?
|
| Piperidines | 1 | 2004 | 198 | 0.200 |
Why?
|
| United States Department of Veterans Affairs | 3 | 2016 | 656 | 0.200 |
Why?
|
| Alzheimer Disease | 4 | 2015 | 764 | 0.200 |
Why?
|
| Neuropsychological Tests | 7 | 2013 | 924 | 0.190 |
Why?
|
| Pilot Projects | 5 | 2025 | 1389 | 0.180 |
Why?
|
| Neoplasms | 1 | 2015 | 2758 | 0.180 |
Why?
|
| Internationality | 1 | 2020 | 129 | 0.170 |
Why?
|
| Parasomnias | 1 | 2019 | 4 | 0.170 |
Why?
|
| Unconsciousness | 1 | 2019 | 17 | 0.170 |
Why?
|
| Combat Disorders | 1 | 2019 | 22 | 0.170 |
Why?
|
| Dreams | 1 | 2019 | 20 | 0.170 |
Why?
|
| Tremor | 1 | 2020 | 129 | 0.160 |
Why?
|
| Fatigue | 3 | 2010 | 216 | 0.160 |
Why?
|
| Activities of Daily Living | 3 | 2015 | 404 | 0.160 |
Why?
|
| Sleep | 1 | 2021 | 344 | 0.150 |
Why?
|
| Evaluation Studies as Topic | 2 | 2008 | 258 | 0.150 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2015 | 713 | 0.150 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2019 | 94 | 0.150 |
Why?
|
| Hippocampus | 1 | 2003 | 819 | 0.150 |
Why?
|
| Interview, Psychological | 1 | 2018 | 97 | 0.150 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 122 | 0.140 |
Why?
|
| Phenotype | 3 | 2021 | 4221 | 0.140 |
Why?
|
| Brain Concussion | 1 | 2019 | 226 | 0.140 |
Why?
|
| Substance-Related Disorders | 2 | 2018 | 455 | 0.130 |
Why?
|
| Public Housing | 1 | 2016 | 7 | 0.130 |
Why?
|
| Age of Onset | 6 | 2014 | 581 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2010 | 3074 | 0.130 |
Why?
|
| Psychiatry | 1 | 2019 | 262 | 0.130 |
Why?
|
| Elective Surgical Procedures | 1 | 2016 | 158 | 0.130 |
Why?
|
| Suicidal Ideation | 1 | 2018 | 194 | 0.120 |
Why?
|
| Apathy | 1 | 2015 | 9 | 0.120 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2020 | 371 | 0.120 |
Why?
|
| Mass Screening | 1 | 2020 | 785 | 0.120 |
Why?
|
| Epilepsy | 1 | 2002 | 857 | 0.110 |
Why?
|
| Motor Skills Disorders | 2 | 2014 | 9 | 0.110 |
Why?
|
| Disabled Persons | 1 | 2015 | 99 | 0.110 |
Why?
|
| Heterozygote | 3 | 2014 | 672 | 0.110 |
Why?
|
| Analysis of Variance | 4 | 2016 | 1008 | 0.110 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 216 | 0.110 |
Why?
|
| ROC Curve | 2 | 2020 | 555 | 0.110 |
Why?
|
| Research Design | 2 | 2015 | 678 | 0.110 |
Why?
|
| Mental Health | 2 | 2014 | 345 | 0.110 |
Why?
|
| Patient Readmission | 1 | 2016 | 368 | 0.110 |
Why?
|
| Odds Ratio | 3 | 2011 | 1244 | 0.110 |
Why?
|
| Role | 1 | 2013 | 26 | 0.100 |
Why?
|
| Clinical Trials as Topic | 2 | 2015 | 1084 | 0.100 |
Why?
|
| Movement | 1 | 2014 | 166 | 0.100 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 224 | 0.100 |
Why?
|
| Schizophrenia | 1 | 2015 | 299 | 0.100 |
Why?
|
| Mutation | 4 | 2010 | 5764 | 0.100 |
Why?
|
| Diagnosis, Differential | 4 | 2007 | 1876 | 0.100 |
Why?
|
| Early Diagnosis | 1 | 2013 | 178 | 0.100 |
Why?
|
| Convergence, Ocular | 1 | 2011 | 2 | 0.100 |
Why?
|
| Dopamine Agents | 1 | 2011 | 28 | 0.100 |
Why?
|
| Memory Disorders | 2 | 2004 | 235 | 0.090 |
Why?
|
| Independent Living | 1 | 2012 | 65 | 0.090 |
Why?
|
| Ocular Motility Disorders | 1 | 2011 | 38 | 0.090 |
Why?
|
| Behavior Therapy | 1 | 2013 | 256 | 0.090 |
Why?
|
| Point Mutation | 2 | 2010 | 348 | 0.090 |
Why?
|
| Antidepressive Agents | 1 | 2013 | 288 | 0.090 |
Why?
|
| Oculomotor Muscles | 1 | 2011 | 63 | 0.090 |
Why?
|
| Supranuclear Palsy, Progressive | 1 | 2010 | 29 | 0.090 |
Why?
|
| Database Management Systems | 1 | 2010 | 31 | 0.090 |
Why?
|
| Societies, Scientific | 1 | 2010 | 26 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2013 | 473 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 3 | 2005 | 1112 | 0.090 |
Why?
|
| Databases as Topic | 1 | 2010 | 71 | 0.090 |
Why?
|
| Comparative Effectiveness Research | 1 | 2010 | 66 | 0.090 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 641 | 0.090 |
Why?
|
| Glucosylceramidase | 1 | 2010 | 27 | 0.090 |
Why?
|
| United States | 6 | 2019 | 10651 | 0.090 |
Why?
|
| alpha-Synuclein | 3 | 2005 | 114 | 0.090 |
Why?
|
| Quality of Life | 5 | 2021 | 1928 | 0.080 |
Why?
|
| Delivery of Health Care | 1 | 2015 | 606 | 0.080 |
Why?
|
| Atomoxetine Hydrochloride | 1 | 2009 | 15 | 0.080 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 1072 | 0.080 |
Why?
|
| Primary Health Care | 1 | 2015 | 752 | 0.080 |
Why?
|
| Guidelines as Topic | 1 | 2010 | 197 | 0.080 |
Why?
|
| Genetic Counseling | 1 | 2010 | 225 | 0.080 |
Why?
|
| Psychological Tests | 1 | 2009 | 89 | 0.080 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 2008 | 7 | 0.080 |
Why?
|
| Substantia Nigra | 1 | 2008 | 33 | 0.070 |
Why?
|
| Health Planning Guidelines | 1 | 2008 | 32 | 0.070 |
Why?
|
| Lewy Body Disease | 2 | 2004 | 18 | 0.070 |
Why?
|
| Caregivers | 1 | 2013 | 571 | 0.070 |
Why?
|
| Movement Disorders | 1 | 2010 | 221 | 0.070 |
Why?
|
| Prefrontal Cortex | 1 | 2009 | 178 | 0.070 |
Why?
|
| Stroke | 1 | 2014 | 955 | 0.070 |
Why?
|
| Young Adult | 5 | 2020 | 8836 | 0.070 |
Why?
|
| Education | 1 | 2007 | 105 | 0.070 |
Why?
|
| Cohort Studies | 4 | 2020 | 4703 | 0.070 |
Why?
|
| MEDLINE | 1 | 2006 | 20 | 0.070 |
Why?
|
| Adrenergic Agonists | 1 | 2006 | 11 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2016 | 12123 | 0.070 |
Why?
|
| Motivation | 1 | 2008 | 314 | 0.070 |
Why?
|
| Databases, Factual | 3 | 2020 | 1171 | 0.070 |
Why?
|
| Deep Brain Stimulation | 1 | 2011 | 396 | 0.070 |
Why?
|
| Emotions | 1 | 2008 | 359 | 0.060 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2006 | 96 | 0.060 |
Why?
|
| Bipolar Disorder | 1 | 2009 | 346 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 1140 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 1 | 2009 | 334 | 0.060 |
Why?
|
| Neuroprotective Agents | 1 | 2006 | 150 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2016 | 3016 | 0.060 |
Why?
|
| Plaque, Amyloid | 1 | 2004 | 63 | 0.060 |
Why?
|
| Mammillary Bodies | 1 | 2003 | 2 | 0.060 |
Why?
|
| Diencephalon | 1 | 2003 | 10 | 0.060 |
Why?
|
| Consensus | 1 | 2007 | 606 | 0.060 |
Why?
|
| Risk | 2 | 2020 | 745 | 0.060 |
Why?
|
| Reproducibility of Results | 4 | 2013 | 2826 | 0.050 |
Why?
|
| Ubiquitin | 1 | 2004 | 141 | 0.050 |
Why?
|
| Genetic Testing | 4 | 2010 | 994 | 0.050 |
Why?
|
| Reference Values | 1 | 2003 | 697 | 0.050 |
Why?
|
| Age Factors | 3 | 2018 | 2803 | 0.050 |
Why?
|
| Cerebellar Diseases | 1 | 2002 | 75 | 0.050 |
Why?
|
| Cerebral Cortex | 1 | 2004 | 447 | 0.050 |
Why?
|
| Huntington Disease | 1 | 2002 | 141 | 0.050 |
Why?
|
| Nitric Oxide | 1 | 2004 | 439 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2005 | 747 | 0.050 |
Why?
|
| Aging | 1 | 2008 | 1176 | 0.050 |
Why?
|
| Synucleins | 3 | 2005 | 13 | 0.050 |
Why?
|
| Neurons | 2 | 2008 | 1935 | 0.040 |
Why?
|
| Genotype | 3 | 2010 | 2533 | 0.040 |
Why?
|
| International Cooperation | 2 | 2011 | 157 | 0.040 |
Why?
|
| Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 | 2 | 2010 | 19 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2021 | 278 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2011 | 423 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2004 | 1590 | 0.040 |
Why?
|
| Risk Factors | 4 | 2015 | 10016 | 0.040 |
Why?
|
| Afghan Campaign 2001- | 1 | 2019 | 117 | 0.040 |
Why?
|
| Iraq War, 2003-2011 | 1 | 2019 | 126 | 0.040 |
Why?
|
| Community Mental Health Services | 1 | 2019 | 38 | 0.040 |
Why?
|
| Adolescent | 4 | 2020 | 19096 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2020 | 367 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2010 | 713 | 0.040 |
Why?
|
| Cognition | 2 | 2015 | 736 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 2018 | 153 | 0.040 |
Why?
|
| Probability | 1 | 2018 | 321 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2010 | 338 | 0.040 |
Why?
|
| Disease Progression | 2 | 2014 | 2023 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 2014 | 0.030 |
Why?
|
| Telephone | 1 | 2015 | 110 | 0.030 |
Why?
|
| Nurses | 1 | 2015 | 63 | 0.030 |
Why?
|
| Self Report | 1 | 2018 | 509 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2015 | 190 | 0.030 |
Why?
|
| Touch | 1 | 2014 | 34 | 0.030 |
Why?
|
| Pain | 1 | 2017 | 470 | 0.030 |
Why?
|
| Electromyography | 1 | 2014 | 163 | 0.030 |
Why?
|
| Functional Laterality | 1 | 2014 | 181 | 0.030 |
Why?
|
| Posture | 1 | 2014 | 152 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2015 | 450 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2020 | 3239 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2015 | 752 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2003 | 3544 | 0.020 |
Why?
|
| Models, Neurological | 1 | 2013 | 202 | 0.020 |
Why?
|
| Databases, Bibliographic | 1 | 2012 | 20 | 0.020 |
Why?
|
| Carbidopa | 1 | 2011 | 18 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2015 | 529 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1308 | 0.020 |
Why?
|
| Sensation | 1 | 2011 | 58 | 0.020 |
Why?
|
| Levodopa | 1 | 2011 | 90 | 0.020 |
Why?
|
| Length of Stay | 1 | 2016 | 1289 | 0.020 |
Why?
|
| Brain | 3 | 2010 | 2962 | 0.020 |
Why?
|
| Syndrome | 1 | 2013 | 1115 | 0.020 |
Why?
|
| Jews | 1 | 2010 | 32 | 0.020 |
Why?
|
| Sex Factors | 1 | 2014 | 1261 | 0.020 |
Why?
|
| Decision Making | 1 | 2015 | 651 | 0.020 |
Why?
|
| Executive Function | 1 | 2010 | 105 | 0.020 |
Why?
|
| Visual Perception | 1 | 2010 | 124 | 0.020 |
Why?
|
| Attention | 1 | 2010 | 195 | 0.020 |
Why?
|
| Telemedicine | 1 | 2015 | 426 | 0.020 |
Why?
|
| Cell Line | 2 | 2005 | 2771 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 279 | 0.020 |
Why?
|
| Physicians | 1 | 2015 | 583 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2010 | 767 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 2009 | 169 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 790 | 0.020 |
Why?
|
| Hospitals | 1 | 2011 | 392 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 1238 | 0.020 |
Why?
|
| Stereotaxic Techniques | 1 | 2008 | 71 | 0.020 |
Why?
|
| National Institute of Mental Health (U.S.) | 1 | 2007 | 13 | 0.020 |
Why?
|
| Memory | 1 | 2010 | 361 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2011 | 807 | 0.020 |
Why?
|
| Publishing | 1 | 2007 | 108 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 1305 | 0.020 |
Why?
|
| Lewy Bodies | 1 | 2004 | 11 | 0.020 |
Why?
|
| Formates | 1 | 2004 | 13 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 1798 | 0.020 |
Why?
|
| Epitope Mapping | 1 | 2005 | 78 | 0.010 |
Why?
|
| MPTP Poisoning | 1 | 2004 | 2 | 0.010 |
Why?
|
| Nitric Oxide Donors | 1 | 2004 | 23 | 0.010 |
Why?
|
| DNA Primers | 1 | 2005 | 660 | 0.010 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2004 | 39 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 2109 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2005 | 408 | 0.010 |
Why?
|
| Registries | 1 | 2010 | 1395 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 2004 | 186 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2005 | 326 | 0.010 |
Why?
|
| Catalytic Domain | 1 | 2004 | 159 | 0.010 |
Why?
|
| Cell Death | 1 | 2004 | 243 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2009 | 1475 | 0.010 |
Why?
|
| tau Proteins | 1 | 2004 | 189 | 0.010 |
Why?
|
| Exons | 1 | 2005 | 794 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2010 | 16039 | 0.010 |
Why?
|
| Transfection | 1 | 2004 | 1068 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2004 | 555 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 1688 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2011 | 6027 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 1386 | 0.010 |
Why?
|
| Personality Disorders | 1 | 2002 | 151 | 0.010 |
Why?
|
| Prognosis | 1 | 2009 | 4513 | 0.010 |
Why?
|
| Animals | 3 | 2007 | 33791 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2005 | 2395 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2005 | 3042 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2004 | 1017 | 0.010 |
Why?
|
| Mice | 2 | 2005 | 17538 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2004 | 3719 | 0.010 |
Why?
|